AIM:APH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Alliance Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.1%

APH

-0.4%

GB Pharmaceuticals

3.7%

GB Market


1 Year Return

-3.1%

APH

25.0%

GB Pharmaceuticals

-9.5%

GB Market

Return vs Industry: APH underperformed the UK Pharmaceuticals industry which returned 24.7% over the past year.

Return vs Market: APH exceeded the UK Market which returned -11% over the past year.


Shareholder returns

APHIndustryMarket
7 Day3.1%-0.4%3.7%
30 Day1.5%2.4%10.8%
90 Day-3.2%8.5%-5.0%
1 Year-1.1%-3.1%29.6%25.0%-5.1%-9.5%
3 Year56.5%47.6%40.2%23.7%-1.7%-13.7%
5 Year115.8%93.6%88.4%51.1%16.4%-9.7%

Price Volatility Vs. Market

How volatile is Alliance Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alliance Pharma undervalued compared to its fair value and its price relative to the market?

31.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: APH (£0.76) is trading below our estimate of fair value (£1.1)

Significantly Below Fair Value: APH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APH is poor value based on its PE Ratio (15.8x) compared to the Pharmaceuticals industry average (15.7x).

PE vs Market: APH is poor value based on its PE Ratio (15.8x) compared to the UK market (15x).


Price to Earnings Growth Ratio

PEG Ratio: APH is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: APH is good value based on its PB Ratio (1.5x) compared to the GB Pharmaceuticals industry average (5x).


Next Steps

Future Growth

How is Alliance Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

7.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APH's forecast earnings growth (7.4% per year) is above the savings rate (1.2%).

Earnings vs Market: APH's earnings (7.4% per year) are forecast to grow slower than the UK market (20.5% per year).

High Growth Earnings: APH's earnings are forecast to grow, but not significantly.

Revenue vs Market: APH's revenue (4.8% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: APH's revenue (4.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: APH's Return on Equity is forecast to be low in 3 years time (9.2%).


Next Steps

Past Performance

How has Alliance Pharma performed over the past 5 years?

17.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APH has high quality earnings.

Growing Profit Margin: APH's current net profit margins (18.4%) are higher than last year (15.5%).


Past Earnings Growth Analysis

Earnings Trend: APH's earnings have grown by 17% per year over the past 5 years.

Accelerating Growth: APH's earnings growth over the past year (36.3%) exceeds its 5-year average (17% per year).

Earnings vs Industry: APH earnings growth over the past year (36.3%) underperformed the Pharmaceuticals industry 36.3%.


Return on Equity

High ROE: APH's Return on Equity (9.1%) is considered low.


Next Steps

Financial Health

How is Alliance Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: APH's short term assets (£65.0M) exceed its short term liabilities (£24.2M).

Long Term Liabilities: APH's short term assets (£65.0M) do not cover its long term liabilities (£109.3M).


Debt to Equity History and Analysis

Debt Level: APH's debt to equity ratio (28.1%) is considered satisfactory.

Reducing Debt: APH's debt to equity ratio has reduced from 32.1% to 28.1% over the past 5 years.

Debt Coverage: APH's debt is well covered by operating cash flow (46.4%).

Interest Coverage: APH's interest payments on its debt are well covered by EBIT (10x coverage).


Balance Sheet


Next Steps

Dividend

What is Alliance Pharma's current dividend yield, its reliability and sustainability?

2.38%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: APH is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Peter Butterfield (43yo)

2.08yrs

Tenure

UK£1,734,693

Compensation

Mr. Peter Jonathan Butterfield has been Chief Executive Officer of Alliance Pharma plc since May 01, 2018. Mr. Butterfield served as Deputy Chief Executive Officer and Chief Operating Officer of Alliance P ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD2.19M) is above average for companies of similar size in the UK market ($USD932.71K).

Compensation vs Earnings: Peter's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Butterfield
CEO & Executive Director2.08yrsUK£1.73m0.078% £313.5k
Andrew Franklin
CFO & Executive Director4.75yrsUK£778.53k0.024% £97.6k
Stephen Kidner
Chief Scientific & Operations Officerno datano datano data
Daniel Thomas
Chief Corporate Development Officerno datano datano data
Janice Timberlake
Chief People and Infrastructure Officerno datano datano data
Steve Lobb
Head of Hydromolno datano datano data
David Hope
Head of Secondary Careno datano datano data
Alex Duggan
Chief Commercial Officer6.08yrsno datano data
Rajiv Ghidiyal
Head of APACno datano datano data
Karim Husny
Head of International4.42yrsno datano data

4.6yrs

Average Tenure

Experienced Management: APH's management team is considered experienced (4.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Butterfield
CEO & Executive Director2.08yrsUK£1.73m0.078% £313.5k
Andrew Franklin
CFO & Executive Director4.75yrsUK£778.53k0.024% £97.6k
Nigel Clifford
Independent Non-Executive Director5.42yrsUK£42.85k0.034% £137.3k
Jo LeCouilliard
Independent Non-Executive Director1.42yrsUK£37.85kno data
Richard Crispin Jones
Independent Non-Executive Director1.42yrsUK£41.60k0.0028% £11.4k
David Cook
Independent Non-Executive Chairman2.25yrsUK£76.07k0.019% £77.8k

3.5yrs

Average Tenure

53yo

Average Age

Experienced Board: APH's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Alliance Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alliance Pharma plc
  • Ticker: APH
  • Exchange: AIM
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£403.559m
  • Shares outstanding: 531.00m
  • Website: https://www.alliancepharmaceuticals.com

Number of Employees


Location

  • Alliance Pharma plc
  • Avonbridge House
  • Bath Road
  • Chippenham
  • Wiltshire
  • SN15 2BB
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2003
DVLDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2003

Biography

Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes pharmaceutical and other medical products. It owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Xonvea, Flamma Franchise, Aloclair, Hydromol, Forceval, Haemopressin, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 21:00
End of Day Share Price2020/06/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.